Table 1.
Comparison of clinical characteristics of patients with t(11;19) (q23;p13.1) and those with t(11;19)(q23;p13.3)
| Characteristic | t(11;19) (q23;p13.1) AML (n = 19) |
t(11;19) (q23;p13.3) AML (n = 13)a |
P-valueb | t(11;19) (q23;p13.3) ALL (n=3) |
|---|---|---|---|---|
| Age, y | 0.42 | |||
| Median | 54 | 38 | 79 | |
| Range | 20–70 | 25–84 | 30–79 | |
| Age group, n (%) | 1.00 | |||
| <60 y | 13 (68) | 9 (69) | 1 (33) | |
| ≥60 y | 6 (32) | 4 (31) | 2 (67) | |
| Female sex, n (%) | 11 (58) | 9 (69) | 0.71 | 3 (100) |
| Race, n (%) | 1.00 | |||
| White | 15 (83) | 11 (85) | 2 (67) | |
| Non-white | 3 (17) | 2 (15) | 1 (33) | |
| Hemoglobin, g/dl | 0.51 | |||
| Median | 9.1 | 9.5 | 12.5 | |
| Range | 2.8–15.8 | 6.2–12.0 | 7.7–13.8 | |
| Platelet count, × 109/l | 1.00 | |||
| Median | 49 | 56 | 66 | |
| Range | 16–163 | 20–184 | 11–165 | |
| WBC, × 109/l | 0.14 | |||
| Median | 29.4 | 10.0 | 92.5 | |
| Range | 2.1–97.5 | 2.3–80.7 | 11.8–231.9 | |
| Bone marrow blasts, % | 0.003 | |||
| Median | 57 | 87 | 90 | |
| Range | 26–93 | 45–96 | 65–94 | |
| Blood blasts, % | 0.004 | |||
| Median | 10 | 58 | 46 | |
| Range | 0–75 | 2–86 | 10–98 | |
| Therapy-related leukemia, n (%) |
0.20 | |||
| Yes | 0 (0) | 2 (15) | 0 (0) | |
| No | 19 (100) | 11 (85) | 3 (100) | |
| FAB (centrally reviewed), n (%) |
— | NR | ||
| M0 | 0 (0) | 1 (9) | ||
| M1 | 1 (6) | 1 (9) | ||
| M2 | 3 (17) | 0 (0) | ||
| M4 | 7 (39) | 0 (0) | ||
| M5 | 7 (39) | 6 (55) | ||
| M6 | 0 (0) | 0 (0) | ||
| Other | 0 (0) | 3 (27) | ||
| Extramedullary involvement, n (%) |
5 (29) | 3 (27) | 1.00 | 0 (0) |
| Transplantation in CR1, n (%) |
1.00 | |||
| Allo | 2 (11) | 1 (8) | 1 (33) | |
| Auto | 2 (11) | 1 (8) | 0 (0) | |
| None | 15 (78) | 11 (85) | 2 (67) | |
| Translocation (11;19), n (%) |
0.07 | |||
| Occurring as a sole abnormality |
14 (74) | 5 (38) | 2 (67) | |
| With additional abnormalities |
5 (26) | 8 (62) | 1 (33) | |
| Complete remission, n (%) |
9 (47) | 8 (62) | 0.49 | 2 (67) |
| Disease-free survival | 0.78 | 2.1 and 7.9 mo | ||
| Median, months | 5.6 | 9.7 | ||
| % Disease-free at 12 months, (95% CI) |
33 (8–62) | 25 (4–56) | ||
| % Disease-free at 60 months, (95% CI) |
22 (3–51) | 25 (4–56) | ||
| Overall survival | 0.59 | 0.8, 5.2 and 8.8 mo |
||
| Median, months | 8.2 | 10.0 | ||
| % Alive at 12 months, % (95% CI) |
21 (7–41) | 46 (19–70) | ||
| % Alive at 60 months, % (95% CI) |
11 (2–28) | 15 (2–39) |
Abbreviations: allo, allogeneic hematopoietic stem-cell transplantation; auto, autologous hematopoietic stem-cell transplantation; CI, confidence interval; CR1, first complete remission, FAB, French-American-British classification; mo, months; n, number; NR, not reported; WBC, white blood count; y, years.
a
Includes one patient with ambiguous lineage acute leukemia.
b
P-values for categorical variables are from Fisher’s exact test, P-values for continuous variables are from Wilcoxon rank sum test for comparisons between AML patients with t(11;19)(q23;p13.1) and those with t(11;19)(q23;p13.3).